This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Dermatol. 1998;134:257-258.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

PERINATAL transmission of human immunodeficiency virus (HIV) accounts for virtually all new HIV infections in children. Through 1993, an estimated 15,000 HIV-infected children were born to HIV-positive women in the United States. In 1994, clinical trials demonstrated a two-thirds reduction in the risk for perinatal transmission associated with treatment of HIV-infected pregnant women and their infants with zidovudine (ZDV) therapy. The Public Health Service (PHS) issued guidelines for the use of ZDV to reduce perinatal transmission in August 1994 and for universal HIV counseling and voluntary testing of pregnant women in July 1995. This report describes increases in HIV testing and use of ZDV treatment among HIV-infected mothers and a continued substantial decline in the incidence of acquired immunodeficiency syndrome (AIDS) during 1992-1996 among children who were infected through perinatal HIV transmission.

For states that conduct HIV surveillance, characteristics were examined for children born to HIV-infected mothers (i.e., perinatally exposed) . . . [Full Text of this Article]

Perinatal HIV Surveillance


Characteristics of Perinatally Acquired AIDS Cases

Trends in Perinatally Acquired AIDS
Editorial Note:

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?